Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -35.59% | 43.63% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -35.59% | 43.63% | |||
| Cost of Revenue | -3.31% | 0.89% | |||
| Gross Profit | -2,658.97% | 104.30% | |||
| SG&A Expenses | 38.61% | -3.48% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.79% | 0.02% | |||
| Operating Income | -184.79% | 57.51% | |||
| Income Before Tax | -80.29% | 33.67% | |||
| Income Tax Expenses | 833.33% | -- | |||
| Earnings from Continuing Operations | -80.54% | 33.69% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -80.54% | 33.69% | |||
| EBIT | -184.79% | 57.51% | |||
| EBITDA | -187.59% | 57.88% | |||
| EPS Basic | -79.40% | 37.08% | |||
| Normalized Basic EPS | -79.12% | 37.05% | |||
| EPS Diluted | -79.40% | 37.08% | |||
| Normalized Diluted EPS | -79.12% | 37.05% | |||
| Average Basic Shares Outstanding | 0.64% | 5.38% | |||
| Average Diluted Shares Outstanding | 0.64% | 5.38% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||